Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-lin...
Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, ...
RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma ( Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
4 Jun 2021
Rare inherited pathogenic germline variants observed in sporadic paediatric neur...
Dr Emily Blauel - Children’s Hospital of Philadelphia, Philadelphia, USA
Rare inherited pathogenic germline variants observed in sporadic paediatric neuroblastoma cases ( Dr Emily Blauel - Children’s Hospital of Philadelphia, Philadelphia, USA )
11 May 2021
PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small ce...
Dr Sophie Postel-Vinay - Gustave Roussey Cancer Center, Paris, France
PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer ( Dr Sophie Postel-Vinay - Gustave Roussey Cancer Center, Paris, France )
4 May 2021
MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA comp...
Dr Matthew Marx - Mirati Therapeutics, San Diego, USA
MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA complex and target MTAP/CDKN2A-deleted tumours ( Dr Matthew Marx - Mirati Therapeutics, San Diego, USA )
30 Apr 2021
Mechanisms of acquired resistance to KRAS G12C inhibition in cancer
Dr Mark Awad - Dana-Farber Cancer Institute, Boston, USA
Mechanisms of acquired resistance to KRAS G12C inhibition in cancer ( Dr Mark Awad - Dana-Farber Cancer Institute, Boston, USA )
26 Apr 2021
OncoAlert and ecancer weekly roundup for April 19 - 25, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for April 19 - 25, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
26 Apr 2021
CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients w...
Dr Robin Portner - The Christie NHS Foundation Trust, Manchester, UK
CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients with limited-stage SCLC ( Dr Robin Portner - The Christie NHS Foundation Trust, Manchester, UK )
19 Apr 2021
AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-onc...
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )
16 Apr 2021
Phase III randomised trial comparing tebentafusp with investigator’s choice in f...
Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany
Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma ( Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany )
16 Apr 2021
Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in ...
Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US
Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma ( Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US )
16 Apr 2021
SMMART Program: A multi-omics tumour board with a focus on breast cancer
Dr Ben Kong - Oregon Health & Science University, Portland, USA
SMMART Program: A multi-omics tumour board with a focus on breast cancer ( Dr Ben Kong - Oregon Health & Science University, Portland, USA )
13 Apr 2021
Clinical validation of a targeted methylation-based multi-cancer early detection...
Dr Eric Klein - Cleveland Clinic, Cleveland, USA
Clinical validation of a targeted methylation-based multi-cancer early detection test ( Dr Eric Klein - Cleveland Clinic, Cleveland, USA )
13 Apr 2021